These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35402130)

  • 1. A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment.
    Yoshida T; Tanaka T; Shindo T; Kyoda Y; Hashimoto K; Kobayashi K; Hasegawa T; Masumori N
    Int Cancer Conf J; 2022 Apr; 11(2):134-137. PubMed ID: 35402130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
    Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
    Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy.
    Nishimura K; Takagi T; Toda N; Yamamoto T; Kondo T; Ishida H; Nagashima Y; Tanabe K
    Mol Clin Oncol; 2017 Mar; 6(3):362-364. PubMed ID: 28451413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma.
    Fujiwara M; Shimada W; Yokoyama M; Koyanagi A; Shintaku H; Fukuda S; Waseda Y; Tanaka H; Yoshida S; Fujii Y
    IJU Case Rep; 2024 Jul; 7(4):293-296. PubMed ID: 38966764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A Case of Myocardial Metastasis of Renal Cell Cancer Treated with Nivolumab].
    Asakura T; Nakai Y; Oka T; Okuda Y; Hatano K; Nakayama M; Kakimoto K; Nishimura K
    Hinyokika Kiyo; 2020 Jul; 66(7):225-228. PubMed ID: 32723977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
    Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in Xp11 translocation renal cell carcinoma.
    Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
    Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
    Sasagawa H; Numakura K; Nakamura G; Kukimoto T; Kikuchi A; Sagehashi R; Yamamoto R; Koizumi A; Nara T; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Habuchi T
    Hinyokika Kiyo; 2021 Dec; 67(12):525-528. PubMed ID: 34991292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy in metastatic renal cell carcinoma.
    Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
    World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
    Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
    Front Oncol; 2019; 9():1033. PubMed ID: 31649889
    [No Abstract]   [Full Text] [Related]  

  • 12. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
    Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review.
    Masago T; Kobayakawa S; Ohtani Y; Taniguchi K; Naka T; Kuroda N; Takahashi C; Isoyama T; Sejima T
    Int Cancer Conf J; 2020 Oct; 9(4):182-186. PubMed ID: 32903928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.
    Azuma T; Sugihara T; Honda S; Yoshizaki U; Niimi F; Tsuru I; Kume H
    Oncol Lett; 2019 Apr; 17(4):4011-4015. PubMed ID: 30881514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
    Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
    Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide-based vaccine.
    Kurahashi R; Motoshima T; Fukushima Y; Murakami Y; Yatsuda J; Yamaguchi T; Sugiyama Y; Fukushima S; Komohara Y; Suekane S; Kamba T
    IJU Case Rep; 2020 Mar; 3(2):44-48. PubMed ID: 32743467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report.
    Zhao J; Dai K; Xie J; Fang C; Chen N; Dai J; Xu D
    Front Pharmacol; 2022; 13():927299. PubMed ID: 36034832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma].
    Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Keilholz U; Kuczyk MA
    Aktuelle Urol; 2020 Dec; 51(6):572-581. PubMed ID: 33027832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.